Neuralink Has About 26 Implant Patients vs Synchron’s 15

Synchron has implanted its brain device in 15 people, five more since last year, its CEO Thomas Oxley told Fortune in a report published Saturday. Over the same period, Neuralink went from seven patients to about 26, Fortune reported. “They’re going fast,” Oxley said of Neuralink.

That makes Neuralink’s patient count about 3.7 times what it was a year ago, against 1.5 times for Synchron (our arithmetic on the counts in Fortune’s report). In the same report, a spokesperson for Merge Labs, the brain-computer interface start-up Sam Altman co-founded, said it expects to have more to share on its product in “a couple months.”

Business Pill · Free Cash Flow

An evergreen Business Engineer explainer. It teaches the general idea only and does not discuss this report.

The key insight: Neuralink has about 26 people using its brain implant, up from seven a year ago, against 15 for Synchron, Fortune reported; Altman’s Merge Labs says more on its product is ‘a couple months’ away.

What a Brain-Computer Interface Does

A brain-computer interface, or BCI, reads electrical signals from neurons and turns them into commands for a computer, so a person can move a cursor or type by thinking. Neuralink’s N1 implant has 64 wires, each thinner than a human hair, with electrodes that pick up those signals, Fortune reported.

All of Neuralink’s roughly 26 users have severe disabilities and use the device in its testing phase, according to Fortune. No brain implant is yet on sale in the US; companies have to pass a pivotal study before the Food and Drug Administration can approve one for patients with clearly defined conditions.

Implanted patients a year ago and now, per Fortune (Synchron's year-ago figure is our arith
Implanted patients a year ago and now, per Fortune (Synchron’s year-ago figure is our arithmetic).

The Race in Numbers

Neuralink has raised $1.3 billion, more than double the next-best-funded brain-implant company, Fortune reported. Synchron was valued at nearly $1 billion in its latest round and is “neck and neck” with Neuralink in the FDA process, the magazine said. Synchron’s Stentrode does not need a craniotomy, the opening of the skull that Neuralink’s surgery uses.

Oxley told Fortune that Synchron is preparing a more powerful device that will reach more parts of the brain, with a launch coming “soon.” Neuralink announced in June 2026 its first procedure that did not break the dura, a protective layer of the brain, Fortune reported.

Merge Labs raised $252 million in January, Bloomberg reported, and OpenAI invested in it, Fortune said. Its goal is a more “seamless” link between people and AI; the spokesperson did not reveal the product. Elsewhere, Science Corp, led by Neuralink co-founder Max Hodak, won European approval in July 2026 for a vision-restoring device and implanted its first patient in October, per Fortune.

China Is Moving Too

China approved the world’s first commercially available BCI in March, Fortune reported. Oxley called the industry there “very fast, very active, and very dynamic,” and when asked if that makes him nervous, he said: “Yes.”

The Structural Read

As we read it, the gap is now in patient numbers, not just funding: Neuralink added 19 people over the year to Synchron’s five (our arithmetic).

As we read it, Merge Labs’ ‘couple months’ sets a near date for a third, AI-first approach to join the race.

Thomas Oxley, Synchron CEO, to Fortune

“They’re going fast”

Three Implications

FOR PATIENTS no brain implant is on sale in the US yet; all of Neuralink’s users are in its testing phase (Fortune).

FOR THE COMPANIES Neuralink leads on funding ($1.3 billion) and patients, while Synchron says a more powerful device is coming ‘soon’ (Fortune).

FOR AI OpenAI has invested in Merge Labs, whose goal is a more ‘seamless’ link with AI (Fortune).

What Is Not Established

Synchron’s count comes from Oxley; Neuralink’s comes from Fortune, which describes it as approximately 26. Merge Labs has not said what its product is or when it will be shown beyond “a couple months.” No implant has US approval yet.

This Week In The AI Supercycle

A World Without an Order, and an AI Central Bank Without a Successor

This week’s issue: the week AI memory stayed largely sold out while the people holding the shares paid: why the AI Supercycle is not a dot-com replay, read through geopolitics, macro and technology, with the gap between building and financing the widest we’ve recorded.

Read the full issue →

Business Engineer Framework

The AI Supercycle

The Business Engineer map of who builds, finances and captures value in AI.

Read the Map of AI →

The Bottom Line

Neuralink has about 26 people using its implant, up from seven a year ago, against Synchron’s 15, Fortune reported, and Altman’s Merge Labs says more on its product is a couple of months away.

97,000+ executives read Business Engineer for the AI strategy frameworks cited by ChatGPT, Claude, and Perplexity.

A note on sourcing. The patient counts, funding figures and quotes are from Fortune’s 21 Nov report, which we read in full. The $252 million raise is from Bloomberg’s January headline; we did not read the full Bloomberg article. The growth multiples are our arithmetic on the counts Oxley gave.

Sources: Fortune, Emily Forlini, ‘Inside the race to put computers in the human brain’, 21 Nov 2026 · Bloomberg, ‘Altman’s Merge Raises $252 Million to Link Brains and Computers’, 15 Jan 2026

Scroll to Top
FourWeekMBA